Atara Biotherapeutics IncNASDAQ:ATRANASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE10.1700
- TODAY'S CHANGE (%)0.4100 (4.2008%)
- Bid / Lots9.3600/ 4
- Ask / Lots10.3200/ 1
- Open / Previous Close9.6700 / 9.7600
- Day Range
- 52 Week Range
- Volume30,482
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ATRA |
|---|---|---|
| 09:32 ET | 1891 | 9.67 |
| 09:36 ET | 600 | 9.8094 |
| 09:38 ET | 100 | 9.8099 |
| 09:39 ET | 693 | 9.73 |
| 09:48 ET | 615 | 9.9148 |
| 09:52 ET | 250 | 9.845 |
| 09:54 ET | 250 | 9.845 |
| 09:59 ET | 100 | 9.85 |
| 10:10 ET | 100 | 9.775 |
| 10:15 ET | 400 | 9.84 |
| 10:19 ET | 2865 | 9.75 |
| 10:26 ET | 100 | 9.8 |
| 10:33 ET | 100 | 9.82 |
| 10:50 ET | 300 | 9.775 |
| 11:00 ET | 2271 | 9.75 |
| 11:02 ET | 100 | 9.8699 |
| 11:09 ET | 100 | 9.78 |
| 11:11 ET | 140 | 9.7749 |
| 11:18 ET | 100 | 9.85 |
| 11:33 ET | 200 | 9.7608 |
| 11:45 ET | 100 | 9.84 |
| 12:07 ET | 100 | 9.785 |
| 12:12 ET | 100 | 9.89 |
| 12:36 ET | 500 | 9.8811 |
| 12:39 ET | 480 | 9.8001 |
| 01:10 ET | 115 | 9.88 |
| 02:06 ET | 950 | 9.915 |
| 02:08 ET | 900 | 9.88 |
| 03:00 ET | 700 | 9.845 |
| 03:02 ET | 4331 | 9.95 |
| 03:16 ET | 1000 | 9.8701 |
| 03:38 ET | 300 | 10.09 |
| 03:56 ET | 100 | 10.095 |
| 03:59 ET | 200 | 10.17 |
Jul 17, 2024
DJ Atara Biotherapeutics Is Maintained at Sell by Goldman Sachs, from 12:08PM ET on Wednesday Jul 17, 2024 by Dow Jones
12:08PM ET on Wednesday Jul 17, 2024 by Dow JonesAtara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel(R) ) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease, from 9:00AM ET on Wednesday Jul 17, 2024 by Dow Jones
9:00AM ET on Wednesday Jul 17, 2024 by Dow JonesPresenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now, from 7:00AM ET on Wednesday Jul 17, 2024 by Dow Jones
7:00AM ET on Wednesday Jul 17, 2024 by Dow Jones
Jul 5, 2024
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4), from 4:01PM ET on Friday Jul 05, 2024 by Dow Jones
4:01PM ET on Friday Jul 05, 2024 by Dow Jones
Jul 3, 2024
Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum, from 7:57PM ET on Wednesday Jul 03, 2024 by Dow Jones
7:57PM ET on Wednesday Jul 03, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Atara Biotherapeutics Inc | 47.9M | -0.2x | --- |
DURECT Corp | 51.2M | -1.9x | --- |
Kezar Life Sciences Inc | 47.9M | -0.5x | --- |
LAVA Therapeutics NV | 55.5M | -1.9x | --- |
Collplant Biotechnologies Ltd | 53.6M | -7.1x | --- |
Curis Inc | 35.5M | -0.7x | --- |
Company Information
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 is in Phase 1 development is being developed as a potential product intended to target B-cell malignancies and autoimmune diseases, based on a next generation 1XX co-stimulatory domain and the innate advantages of EBV T cells as the foundation for an allogeneic CAR T platform.
Contact Information
- Headquarters
- 2380 Conejo Spectrum St, Suite 200THOUSAND OAKS, CA, United States 91320
- Phone
- 805-623-4244
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Carol Gallagher
- President, Chief Executive Officer, Director
- Pascal Touchon
- Chief Financial Officer, Executive Vice President
- Eric Hyllengren
- Executive Vice President, Chief Scientific and Technology Officer
- Anhco Nguyen
- Executive Vice President - Global Head Regulatory Affairs and Quality
- Jill Henrich
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $47.9M |
|---|---|
Revenue (TTM) | $34.7M |
Shares Outstanding | 4.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.49 |
EPS | $-52.93 |
Book Value | $-23.31 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | 1.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -669.19% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
